Inogen Inc — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
On July 6, 2026, Inogen appointed Andrew Reding as Executive Vice President and Chief Operating Officer. Reding receives a $500,000 base salary, target bonus of 70% ($350,000 annualized at target), a $100,000 sign-on bonus, 130,000 RSUs vesting over 3 years, and $2,500 legal fee stipend. Standard severance: 12 months base salary + COBRA if terminated without cause outside change-of-control window; 24 months base salary if terminated without cause during change-of-control period. Reding brings 30+ years med-tech experience from Viant Medical and Hillrom.
Why this rating
Moderate event: new C-suite hire with competitive compensation (~$1M total target comp = ~0.5% of $190M market cap, routine for senior role); no major deal, loss, or strategic shift disclosed; neutral on business direction.
Extracted items
- 5.02 exec change
- 7.01 Reg FD disclosure
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.